key: cord-0074645-5ol6k2qg
authors: Delaporta, P; Kyriakopoulou, D; Ioakeimidou, N; Solomou, E; Binenbaum, I; Toutoudaki, K; Chatzielefteriou, M; Papassotiriou, I; Kattamis, A
title: S124: ADVERSE EVENTS FOLLOWING COVID-19 VACCINATION IN TRANSFUSION-DEPENDENT -THALASSEMIA PATIENTS
date: 2022-01-31
journal: Hemasphere
DOI: 10.1097/01.hs9.0000821464.52797.65
sha: 84302e8b4e14abad4f6cca873098a21e2b1912d4
doc_id: 74645
cord_uid: 5ol6k2qg

nan

Background: Patients with transfusion-dependent-thalassemia (TDT) are considered as increased risk population for severe and/or morbid COVID-19 infection. Timely vaccination is the main preventive method for severe COVID-19. Different adverse events and reactions following vaccination have been reported, with severe ones being extremely rare. TDT patients may have altered immunity due to chronic transfusions, iron overload and chelation therapy, and splenic dysfunction. The safety profile of vaccination in chronically transfused patients with thalassemia has not been reported. Aim: To evaluate the safety profile of COVID-19 vaccines in TDT patients. Patients and Methods: This is a single institution's, retrospective analysis evaluating all TDT patients, older than 18 years old, who had completed the vaccination protocol at least 30 days before data cut-off time (July 20th 2021). Adverse events were reported by patients up to 30 days post each dose. Demographic data and hematological data, including mean hemoglobin levels before and up to 90 days after each dose, were recorded. T-test was performed to investigate changes in hematological profile and transfusion burden post vaccination. Results: 186 patients (median age:45; range:18-61 years old; male/ female:87/99) were included for data analysis corresponding to 53% of all TDT patients followed in our Thalassemia Unit. Distribution of vaccine types were: Comirnaty-BNT162b2 (Pfizer Inc. and BioNTech)90.86% (n =168), Vaxzevria (previously COVID-19 vaccine, AstraZeneca) 1.61% (n=3), Moderna (Moderna TX Inc.) 6.99% (n =13) and JNJ-78436735 (Janssen Pharmaceuticals Companies of Johnson & Johnson) 0.54% (n =2). No patients had confirmed or suspected previous COVID-19 infection. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The incidence of adverse events after 1st and 2nd dose were 43.5% (81/186) and 54.8% (102/186), respectively. Adverse events after 1st dose included pain at injection site 26.3% (n=49), fatigue 9.7%(n=18), fever 5.4% (n=10),headaches 4.3% (n=8), arthralgia and myalgia 2.2% (n=4), and lymphadenopathy 0.5% (n=1). Adverse events after 2nd dose included fever 28.5% (n=53), fatigue 17.7% (n=33), pain at injection site 15.6%(n=29), arthralgia and myalgia 11.3% (n=21), headaches 9.1% (n=17), lymphadenopathy 3.2% (n=6), dizziness 0,5% (n=1), tachycardia 0.5% (n=1), diarrhea/ vomiting 0.05% (n=1) and amaurosis fugax 0.5%: (n=1). No grade 4-5 events or anaphylaxis were observed. Two patients (both males, 51 years and 45 years old, respectively) presented with acute hemolytic crisis with hemoglobinuria in 3rd and 20th day after the second dose with Pfizer/ BioNTech, respectively. They are receiving treatment with corticosteroids without partial response. Both patients had a history of acute hemolysis crisis within the last 3 years. A slight decrease in patients' mean hemoglobin levels was observed three months after vaccination compared to the mean hemoglobin levels before vaccination (mean=9.9 /sd=0.63 g/dL vs mean=9.81 /sd=0.64 g/dl, respectively, p= 0.05). Conclusions: Compared to the vaccine trials, we observed some lower incidence of vaccine-related adverse events in our cohort of TDT patients. A temporary drop in hemoglobin levels may be noted. Of interest, two patients with previous history of alloimmunization, developed hemolysis. Close follow up is required in TDT patients post vaccination.

Thalassaemia International Federation, Guidelines for the management of transfusion dependent thalassaemia (TDT)

A 1 1 University of Cape Town